Navigation Links
GeoVax Phase 2a Clinical Trial Completes Enrollment
Date:10/3/2011

ATLANTA, Oct. 3, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine. The vaccine is being developed for use in uninfected people to prevent infection should they be exposed to the virus. The trial, designated HVTN 205, is being conducted by the HIV Vaccines Trials Network (HVTN), which is funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. A total of 299 participants are enrolled in HVTN 205.

GeoVax also announced the unblinding of data for neutralizing antibody (Ab) responses in part 1 of HVTN 205 – showing elicitation of unexpectedly high response rates of neutralizing antibody for tier 2 isolates of HIV-1.  Of 46 tested vaccine recipients, 50% responded with neutralizing activity for tier 2 clade B isolate RHPA; and 26% with neutralizing antibody for tier 2 clade B isolate SC22.3C2. Neutralizing antibodies can block virus from infecting cells by binding to regions of the virus that mediate entry into cells. The elicitation of neutralizing antibody for tier 2 viruses is an important result because tier 2 viruses represent viruses that undergo the most frequent transmission from an infected person to an uninfected person. A new highly sensitive test was used for conducting neutralization tests, which were done at the HVTN laboratories at Duke University.

"Elicitation of neutralizing antibody is a much sought goal for an HIV/AIDS vaccine," said Harriet Robinson, Ph.D., Chief Scientific Officer of GeoVax. "The field has been trying to achieve this goal by re-engineering the HIV envelope protein that mediates entry into cells. Our vaccines use natural forms of the HIV envelope to raise antibody. We are extremely pleased that our natural f
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
2. GeoVax Labs, Inc. Announces Second Quarter Financial Results
3. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
4. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
5. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
6. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
7. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
8. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
9. GeoVax Labs Engages The Investor Relations Group
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
11. GeoVax Labs, Inc. Plans Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... LAS VEGAS , March 26, 2015 Zimmer ... of a new mobile app designed to serve as a ... Hyaluronate product. For those experiencing knee ... valuable information about the causes of knee pain and helps ... Hyaluronate as a safe and simple non-surgical treatment option. For ...
(Date:3/26/2015)... Californie, 26 mars 2015 Finesse Solutions ... conçu pour les innovateurs, visionnaires et cadres de ... conférence d,une durée de deux jours proposée exclusivement ... dans le centre ville de San ... 2015. Il s,agira d,un forum destiné aux leaders ...
(Date:3/26/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today ... from the Israeli patent office with claims for administering ... damage caused by an increase in blood flow, as ... after a blockage causing a heart attack or in ... can be caused to the heart attack or stroke ...
Breaking Medicine Technology:Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2Finesse Solutions annonce l'événement Cellworld 2015 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3
... NESHER, Israel, April 21 NanoVibronix, a ... surface ultrasound waves,announced that its novel device ... claims of wound healing. PainShield is the ... waves for therapeutic,treatment of wounds. The innovative ...
... - Preclinical Studies Highlight the Ability of PS-Targeting ... Tumors by Changing the Tumor Microenvironment and Mobilizing ... Studies Confirm Peregrine,s PS-Targeting Antibodies Stimulate Dendritic Cell ... of Macrophages to Tumors -DENVER and TUSTIN, Calif., ...
Cached Medicine Technology:NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device 2Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 2Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 3Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 4Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 5Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 6Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 7
(Date:3/26/2015)... Md. (PRWEB) March 26, 2015 ... than $11.3 billion in 2014, according to an ... , The Annapolis-based healthcare real estate (HRE) data ... board members and two new Gold-Level Partners: Harrison ... Investment Services. , MOB transactions still going strong, ...
(Date:3/26/2015)... 2015 Pacific Medical LLC, the leader ... be featured on Innovations with Ed Begley Jr, which ... The episode will repeat on local cable channels ... Pacific Medical home page at: http://www.pacificmedicalsupply.com . ... is reassuring to trust the integrity of the medical ...
(Date:3/26/2015)... On March 5, 2015, Portland Trail ... for the season with a torn Achilles tendon in ... Blazers were competing against Dallas, and was confirmed via ... Silva, M.D., who has treated many professional athletes, voiced ... could be prevented. , "Part of the problem ...
(Date:3/26/2015)... In the key developed markets, the hypertension market value ... to decrease through 2020 at a negative CAGR (0.9%) to ... to 2017 at a 2.6% CAGR and a decline thereafter. ... surging penetration of fixed-dose combination drugs like Azor, Amturnide, Exforge ... and Tekamlo), a hike in the prevalence population to 190 ...
(Date:3/26/2015)... March 26, 2015 In preparation for ... Fitness Revolution, founded by Samir Becic, has issued ... own personal health and fitness, as well as their ... The list includes Sen. Ted Cruz, who has officially ... as all other politicians who have shown interest in ...
Breaking Medicine News(10 mins):Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 2Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 3Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 4Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3
... they are admitted to hospital may be one way to ... today’s BMJ. ,Recent data published by the Health ... 7,000 inpatients have MRSA infections and more than 50,000 inpatients ... of C difficile rose by 5.5% in 2006, whereas MRSA ...
... by blocking the lifesaving effects of aspirin//, a new study ... monstrous," Michael Farkouh, director of clinical trials at Mount Sinai ... ,“Ibuprofen is relatively safe except when we give it ... Farkouh says. "But when given with aspirin, we do we ...
... couple of months, 100,000 doses of the country's first vaccine ... developed it has found no takers //and the expiry date ... year that the High Security Animal Disease Laboratory (HSADL) here ... about 100,000 doses of the vaccine, each costing just 27 ...
... mammograms are more likely to interpret a benign growth ... and experience," and CAD systems do not help detect ... systems use complex algorithms to identify "suspicious" areas of ... which cost $50,000 to $175,000, were approved by FDA ...
... The Food and Drug Administration (FDA) today warned consumers ... Chews and Dog Chews manufactured// and distributed by T.W. ... have the potential to be contaminated with Salmonella, which ... if there is cross contamination, in people, especially children, ...
... Foundation on Wednesday announced that it will spend $500 ... address childhood obesity//, particularly targeting minority children, who are ... ,Nearly 25 million children under age 18 are considered ... medical expenses, according to the foundation. ,The ...
Cached Medicine News:Health News:Ibuprofen Risky for Heart Patients? 2Health News:100,000 Bird Flu Vaccine Doses to Be Destroyed 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: